Quantcast

Latest J&JPRD Stories

2010-10-04 07:01:00

RARITAN, N.J., Oct. 4 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for tapentadol extended release tablets. The application, filed by J&JPRD in late 2009 [see press release at http://www.jnj.com/connect/news/product/20091201_200000], seeks approval to market tapentadol extended...

2010-07-19 07:30:00

RARITAN, N.J., July 19 /PRNewswire/ -- A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release (ER) tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release (CR) tablets. The study found tapentadol ER was associated with a lower overall incidence of gastrointestinal adverse events than oxycodone CR (tapentadol ER, 52.0 percent; oxycodone CR, 64.1 percent) in patients with...

2010-06-26 13:45:00

ORLANDO, Fla., June 26 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 (SGLT2) inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American...

2010-05-07 07:00:00

BALTIMORE, May 7 /PRNewswire/ -- A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain. These data will be presented during a poster session today at the 29th Annual Scientific Meeting of the American Pain Society (APS), and...

2010-05-03 07:00:00

RARITAN, N.J., May 3 /PRNewswire/ -- Data on tapentadol for the relief of acute and chronic pain, as well as patient and prescriber perceptions of oxycodone immediate-release treatments, will be presented at the 29th Annual Scientific Meeting of the American Pain Society (APS) May 6-8, 2010. Four of the 12 poster presentations will review analyses of tapentadol data, including a post-hoc analysis of a Phase 3 tolerability study on NUCYNTA® (tapentadol) tablets for acute...

2010-04-13 10:13:00

RARITAN, N.J., April 13 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for PANCREAZE(TM) (pancrelipase) delayed-release capsules for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. Exocrine pancreatic insufficiency is the inability to properly digest and absorb food due to a lack of enzymes made by...

2010-02-04 07:00:00

SAN ANTONIO, Feb. 4 /PRNewswire/ -- Data from three important studies on tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older, will be discussed during the poster sessions of the 26th Annual Meeting of the American Academy of Pain Medicine (AAPM), February 3-6, 2010 in San Antonio, TX. Following are details about the presentations, which are supported by Johnson & Johnson...

2009-12-30 05:06:00

RARITAN, N.J., Dec. 30 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole. The New Drug Application (NDA) was originally submitted to the FDA in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections. The FDA has requested additional information and...

2009-12-01 16:20:00

RARITAN, N.J., Dec. 1 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older. Chronic pain, defined as pain that persists for long periods of time - usually greater than three...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.